Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI. Vlahovic G, et al. Oncologist. 2018 Jul;23(7):782-790. doi: 10.1634/theoncologist.2016-0377. Epub 2018 Mar 23. Oncologist. 2018. PMID: 29572245 Free PMC article. Clinical Trial.
Activation of tyrosine kinases in cancer.
Vlahovic G, Crawford J. Vlahovic G, et al. Oncologist. 2003;8(6):531-8. doi: 10.1634/theoncologist.8-6-531. Oncologist. 2003. PMID: 14657531 Free article. Review.
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
Vlahovic G, Meadows KL, Uronis HE, Morse MA, Blobe GC, Riedel RF, Zafar SY, Alvarez-Secord A, Gockerman J, Starodub AN, Ready NE, Anderson EL, Bendell JC, Hurwitz HI. Vlahovic G, et al. Cancer Chemother Pharmacol. 2012 Jul;70(1):95-102. doi: 10.1007/s00280-012-1889-8. Epub 2012 May 26. Cancer Chemother Pharmacol. 2012. PMID: 22638798 Free PMC article. Clinical Trial.
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
Affronti ML, Jackman JG, McSherry F, Herndon JE 2nd, Massey EC Jr, Lipp E, Desjardins A, Friedman HS, Vlahovic G, Vredenburgh J, Peters KB. Affronti ML, et al. Among authors: vlahovic g. Oncologist. 2018 Aug;23(8):889-e98. doi: 10.1634/theoncologist.2018-0149. Epub 2018 Apr 17. Oncologist. 2018. PMID: 29666296 Free PMC article. Clinical Trial.
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Czito BG, Vujaskovic Z, Vlahovic G, Bendell J, Cohen KS, Hurwitz HI, Bentley R, Lauwers GY, Poleski M, Wong TZ, Paulson E, Ludwig KA, Jain RK. Willett CG, et al. Among authors: vlahovic g. Nat Clin Pract Oncol. 2007 May;4(5):316-21. doi: 10.1038/ncponc0813. Nat Clin Pract Oncol. 2007. PMID: 17464339 Free PMC article.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Omuro A, et al. Among authors: vlahovic g. Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208. Neuro Oncol. 2018. PMID: 29106665 Free PMC article. Clinical Trial.
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Herbst RS, et al. Among authors: vlahovic g. Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X. Lancet. 2011. PMID: 21621716 Free PMC article. Clinical Trial.
36 results